Related Experiment Video
Updated: Jun 25, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity
Caroline Marty1, Ronan Chaligné, Catherine Lacout
1INSERM, U790, Villejuif 94805, France.
Abstract:
The activating W515L mutation in the thrombopoietin receptor (MPL) has been identified in primary myelofibrosis and essential thrombocythemia. MPL belongs to a subset of the cytokine receptor superfamily that requires the JAK2 kinase for signaling. We examined whether the ligand-independent MPL(W515L) mutant could signal intracellularly. Addition of the endoplasmic reticulum (ER) retention KDEL sequence to the receptor C terminus efficiently locked MPL(W515L) within its natural ER/Golgi maturation pathway. In contrast to cells expressing the parental MPL(W515L), MPL(W515L)-KDEL-expressing FDC-P1 cells were unable to grow autonomously and to produce tumors in nude mice. When observed, tumor nodules resulted from in vivo selection of cells leaking the receptor at their surface. JAK2 co-immunoprecipitated with MPL(W515L)-KDEL but was not phosphorylated. We generated disulfide-bonded MPL(W515L) homodimers by the S402C substitution, both in the normal and KDEL context. Unlike MPL(W515L)-KDEL, MPL(W515L-S402C)-KDEL signaled constitutively and exhibited cell surface localization. These data establish that MPL(W515L) with appended JAK2 matures through the ER/Golgi system in an inactive conformation and suggest that the MPL(W515L)/JAK2 complex requires membrane localization for JAK2 phosphorylation, resulting in autonomous receptor signaling.
Insights
The thrombopoietin receptor (MPL) W515L mutation requires cell surface localization for JAK2 phosphorylation and signaling, crucial for myeloproliferative neoplasms like primary myelofibrosis.
Area of Science:
- Hematology
- Molecular Biology
- Cell Biology
Background:
- The activating W515L mutation in the thrombopoietin receptor (MPL) is implicated in myeloproliferative neoplasms.
- MPL signaling is dependent on the JAK2 kinase.
- Understanding MPL W515L signaling is critical for therapeutic development.
Purpose of the Study:
- To investigate the intracellular signaling of the ligand-independent MPL(W515L) mutant.
- To determine the role of receptor maturation and localization in MPL(W515L) signaling.
- To elucidate the mechanism of JAK2 activation by MPL(W515L).
Main Methods:
- Utilized endoplasmic reticulum (ER) retention KDEL sequence to trap MPL(W515L) in the ER/Golgi pathway.
- Assessed cell growth, tumor formation in nude mice, and JAK2 phosphorylation.
- Generated disulfide-bonded MPL(W515L) homodimers via S402C substitution.
Main Results:
- MPL(W515L)-KDEL, retained in the ER/Golgi, failed to induce autonomous cell growth or tumor formation.
- JAK2 co-immunoprecipitated with MPL(W515L)-KDEL but remained unphosphorylated.
- Disulfide-bonded MPL(W515L-S402C)-KDEL localized to the cell surface, signaled constitutively, and induced JAK2 phosphorylation.
Conclusions:
- The MPL(W515L)/JAK2 complex matures in an inactive conformation within the ER/Golgi.
- Cell surface localization is essential for JAK2 phosphorylation and subsequent autonomous signaling.
- These findings provide insights into the pathogenesis of MPL-driven myeloproliferative neoplasms.
More Related Videos
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Intracellular Signaling Affects Focal Adhesions
Some...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases
Regulation of Angiogenesis and Blood Supply
Amplifying Signals via Enzymatic Cascade

